Equity - Narrative (Details)	9 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) shares	Aug. 31, 2022 shares	Dec. 31, 2021 USD ($)
Equity [Line Items]
Authorized amount (in shares)				10,000,000
Common shares repurchased (in shares)	0	11,702,074
Treasury stock acquired, average cost (in dollars per share) | $ / shares		$ 10.84
Shares remaining available for repurchase (in shares)	6,874,241
Unsettled repurchases | $	$ 0
Series C cumulative convertible preferred, shares outstanding (in shares)	1,935,400		1,935,400
Series C cumulative convertible preferred, liquidation preference | $	$ 96,770,000		$ 96,770,000
OP unit equivalent in common shares	1.13
Partners capital account, shares issued for units redeemed	9,944	33,378
Partners' capital account, exchanges and conversions | $	$ 49,000	$ 177,000
Noncontrolling Interests
Equity [Line Items]
Partners' capital account (in units)	731,000
Series C Cumulative Convertible Preferred Stock
Equity [Line Items]
Series C cumulative convertible preferred, shares outstanding (in shares)	1,935,400
Preferred stock, dividend per annum (in dollars per share) | $ / shares	$ 3.25
Series C cumulative convertible preferred, liquidation preference | $	$ 96,770,000
Convertible preferred stock, conversion ratio (in shares)	2.4339
Preferred stock conversion, threshold conversion price percentage (at least)	1.25
Forward Contracts
Equity [Line Items]
Number of shares sold (in shares)	0	3,649,023
Proceeds from sale of stock | $		$ 38,492,000
Unvested share-based payment awards
Equity [Line Items]
Shares granted (in shares)	70,072	47,505
Grant date fair value | $	$ 714,000	$ 616,000
At-The-Market Program
Equity [Line Items]
Number of shares sold (in shares)	0	0
Sale of stock, authorized amount (up to) | $					$ 350,000,000
Common shares amount available for issuance | $	$ 294,985,000